|
|
Hyperparathyroidism
|
|
Hyperparathyroidism
[an error occurred while processing this directive]
Nutrition, mild hyperparathyroidism, and bone mineral density in ... Nov 14, 2005
In addition to weight and physical activity, the presence of mild hyperparathyroidism was associated with a low BMD of the lumbar spine (P = 0.0062) and the ...
- Am J Clin Nutr (subscription),
The Impatient Patient Oct 26, 2005
...doctor (a good man and a good doctor, who is still my family doctor) told me that a recent blood test indicated that I had "hyperparathyroidism" and that I ...
- TheTyee.ca,
Renal Week Debates on Drugs and the Kidney Nov 12, 2005
...will debate the merits and dangers of calcium-containing phosphate binding agents in treating the secondary hyperparathyroidism and osteodystrophy of patients ...
- Newswise (press release)
ABOUT THE BASQUE COUNTRY Nov 1, 2005
...radius if it cannot be undertaken at the column or hip by means of previous surgical operations, as well as in obese patients or in cases of hyperparathyroidism ...
- EiTB,
Abgenix Announces Third Quarter 2005 Financial Results Oct 25, 2005
...oncology product candidate, panitumumab, and ABX-10241, a fully human antibody being studied for the potential treatment of secondary hyperparathyroidism (SHPT ...
- PR Newswire (press release),
NPS Pharmaceuticals to Promote Allergan's RESTASIS(R) to ... Oct 24, 2005
The company's first FDA-approved product, Sensipar(R) (cinacalcet HCl), is licensed to Amgen Inc. for the treatment of hyperparathyroidism. ...
- Finanzen.net,
Medullary carcinoma of thyroid Oct 26, 2005
Risk factors are a family history of multiple endocrine neoplasia (MEN), a prior history of pheochromocytoma, mucosal neuromas, or hyperparathyroidism. ...
- drkoop.com
BioXell Initiates Phase IIa Trial of its Lead Compound BXL628 in ... Nov 7, 2005
BioXell is also collaborating with ProStrakan to develop Vitamin D3 drug candidates to treat osteoporosis and secondary hyperparathyroidism. ...
- PharmaLive.com (press release),
FDA Safety Labeling Changes: Hectorol, Mevacor, Pulmicort Respules Sep 28, 2005
Doxercalciferol injection is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. ...
- Medscape (subscription)
R&D Business Sep 13, 2005
One key component in the acquisition is Bone Care’s Hectorol, a vitamin D2 pro-hormone product used to treat secondary hyperparathyroidism in patients on ...
- R&D Directions (subscription),
Schaeffer's Daily Market Blog Features Marvel Enterprises, Cisco ... Sep 6, 2005
NASDAQ:NPSP) calcium receptor technology is the launching point for its research and development of treatments for hyperparathyroidism (HPT), osteoporosis, and ...
- Business Wire (press release),
Tumor-Induced Osteomalacia Sep 13, 2005
R has experienced complications of long-term treatment with phosphorus and calcitriol; she has developed both nephrolithiasis and tertiary hyperparathyroidism. ...
- Journal of American Medical Association (subscription),
Reply to MA Weinstock and D Lazovich Sep 27, 2005
Chel VGM, Ooms ME, Popp-Snijders C, et al. Ultraviolet irradiation corrects vitamin D deficiency and suppresses secondary hyperparathyroidism in the elderly. ...
- Am J Clin Nutr (subscription),
NPS Pharma Shares Could See Year-End OverhangJul 27, 2005
..."We continue to have a positive bias towards Sensipar as a novel, first in-class, agent to treat hyperparathyroidism in patients with kidney disease," it said. ...
- Forbes
Abgenix Announces Second Quarter 2005 Financial ResultsJul 26, 2005
...dose Phase 1 study of ABX-PTH, Abgenix's proprietary fully human antibody for the potential treatment of secondary hyperparathyroidism (SHPT) -- Submission of ...
- Yahoo News
R&D BusinessJul 14, 2005
One key component in the acquisition is Bone Care’s Hectorol, a vitamin D2 pro-hormone product used to treat secondary hyperparathyroidism in patients on ...
- R&D Directions (subscription)
Amgen evolutionJul 17, 2005
This set up a hot four years, during which rheumatoid arthritis fighters Kineret and Enbrel, infection drug Neulasta and hyperparathyroidism treatment Sensipar ...
- Rocky Mountain News
Seniors Need to Take Advantage of Medicare Preventive ProgramsJul 15, 2005
...osteoporosis, and persons (1) with vertebral abnormalities, (2) receiving long-term glucocorticoid steroid therapy, (3) with primary hyperparathyroidism, and (4 ...
- SeniorJournal.com
Abbott Reports 17.5 Percent Sales Increase in the Second QuarterJul 13, 2005
On May 27, 2005, the FDA approved Zemplar® (paricalcitol) Capsules for the treatment and prevention of secondary hyperparathyroidism (SHPT) in patients ...
- Yahoo News
Genzyme Reports Second-Quarter GAAP EPS of $0.46, Non-GAAP EPS of ...Jul 14, 2005
Hectorol is a line of vitamin D2 products approved to treat secondary hyperparathyroidism in patients on dialysis and those with earlier stage chronic kidney ...
- Yahoo News
Bone Care aqusition has signicant impactJul 1, 2005
...research of founder Hector DeLuca - currently president and CEO of Deltanoid Pharmaceuticals - and is used to treat secondary hyperparathyroidism in patients ...
- WTN News
This page is updated on a monthly basis if relevant articles are available. If you are looking for further information on
Hyperparathyroidism
you may want to try searching the Internet using the Google search box below.
|
|
|
